ERC-AG-LS7
ERC-AG-LS7
Programme: H2020
89 projects · €209,113,287 total EU contribution (project-level) · 102 participating organizations · 18 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€209,113,287
Countries active
Participant organizations by country (headquarters in CORDIS).
- Italy (19)
- Germany (16)
- UK (13)
- Spain (12)
- Netherlands (11)
- France (5)
- CH (4)
- SE (4)
- NO (3)
- BE (2)
- CY (2)
- DK (2)
- FI (2)
- IL (2)
- EL (1)
- HU (1)
- IE (1)
- US (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- INSERM6 projects · FR
- KU Leuven4 projects · BE
- ERASMUS MC3 projects · NL
- HELSINGIN YLIOPISTO3 projects · FI
- UEDIN3 projects · UK
- UNIVERSITY COLLEGE LONDON3 projects · —
- Leiden University Medical Center2 projects · NL
- CSIC2 projects · ES
- GERMAN CANCER RESEARCH CENTER2 projects · DE
- HSR2 projects · IT
- INGM2 projects · IT
- IRFMN2 projects · IT
Projects
Page 4 of 9
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
Advanced Microfluidics & Diagnostics using Acoustic Holograms – Bio-Phononics Bio-Phononics · 340117 | FP7 | €2,208,594 | €2,208,594 | Details |
Identification and functional validation of drugable targets/pathways for triple negative breast cancer TRIPLE-BC · 322737 | FP7 | €2,495,102 | €2,495,102 | Details |
EPidemiological Left ventriclar Outcomes Research in Europe EPLORE · 294713 | FP7 | €2,391,440 | €2,391,440 | Details |
Deciphering the regulatory T cell repertoire: towards biomarkers and biotherapies for autoimmune diseases TRIPOD · 322856 | FP7 | €2,500,000 | €2,500,000 | Details |
Randomized controlled trial of metformin and dietary restriction to prevent age-related morbid events in people with metabolic syndrome MEMEME · 322752 | FP7 | €2,500,000 | €2,500,000 | Details |
New experimental therapeutic approaches for Parkinson’s disease by direct DA neuronal reprogramming REPROPARK · 340527 | FP7 | €2,415,767 | €2,415,767 | Details |
Noncoding and Translational Modulation of Gene Expression and Epigenetic Changes TRANSLATE · 338999 | FP7 | €2,496,000 | €2,496,000 | Details |
Innovative drugs targeting IDO molecular dynamics in autoimmunity and neoplasia DIDO · 338954 | FP7 | €2,442,078 | €2,442,078 | Details |
Lymphocyte microRNAs in health and disease: Understanding lymphocyte functions through the identification of microRNA target genes and exploiting serum microRNA signatures to monitor immune responses I-MIRNOME · 269022 | FP7 | €2,496,000 | €2,496,000 | Details |
Engineering Cytokines for Super-Affinity Binding to Matrix in Regenerative Medicine CYTRIX · 339147 | FP7 | €2,368,170 | €2,368,170 | Details |